NCT01676649View on ClinicalTrials.gov

Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

February 28, 2017

Study Completion Date

May 31, 2026

Conditions
Untreated Stage III Melanoma or Stage IV Melanoma
Interventions
BIOLOGICAL

Ipilimumab

3 mg/kg

DRUG

Carboplatin

AUC = 6

DRUG

Paclitaxel

175 mg/m2

Trial Locations (1)

H3T 1E2

Jewish General Hospital, Montreal

All Listed Sponsors
lead

Jewish General Hospital

OTHER